Advanced search
Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Email Registration
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. HOOKIPA Pharma Inc.
  6. Summary
    HOOK   US43906K1007

HOOKIPA PHARMA INC.

(HOOK)
  Report
Delayed Nasdaq  -  04:00 2022-09-29 pm EDT
1.460 USD   -2.67%
09/13Transcript : HOOKIPA Pharma Inc. Presents at Morgan Stanley 20th Annual Global Healthcare Conference, Sep-13-2022 12:55 PM
CI
09/07HOOKIPA Pharma to Participate in Upcoming Investor Conferences in September
GL
08/23Truist Securities Lowers HOOKIPA Pharma's Price Target to $11 From $16, Maintains Buy Rating
MT
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
09/23/2022 09/26/2022 09/27/2022 09/28/2022 09/29/2022 Date
1.47(c) 1.45(c) 1.47(c) 1.5(c) 1.46(c) Last
172 104 91 419 60 591 75 781 128 815 Volume
+0.68% -1.36% +1.38% +2.04% -2.67% Change
More quotes
Estimated financial data (e) (USD)
Sales 2022 12,1 M - -
Net income 2022 -76,8 M - -
Net cash position 2022 81,8 M - -
P/E ratio 2022 -1,10x
Yield 2022 -
Sales 2023 18,9 M - -
Net income 2023 -87,0 M - -
Net cash position 2023 79,6 M - -
P/E ratio 2023 -1,18x
Yield 2023 -
Capitalization 79,9 M 79,9 M -
EV / Sales 2022 -0,16x
EV / Sales 2023 0,01x
Nbr of Employees 144
Free-Float 86,6%
More Financials
Company
HOOKIPA Pharma Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing an immunotherapeutic based on its arenavirus platform, which is designed to target and amplify a T cell and immune response to disease. Its replicating and non-replicating technologies are engineered to induce robust and durable antigen-specific CD8+ T cell responses and pathogen-neutralizing antibodies. Its... 
Read more
Sector
Pharmaceuticals
Calendar
11/16Earnings Release
More about the company
Ratings of HOOKIPA Pharma Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C-
More Ratings
All news about HOOKIPA PHARMA INC.
09/13Transcript : HOOKIPA Pharma Inc. Presents at Morgan Stanley 20th Annual Globa..
CI
09/07HOOKIPA Pharma to Participate in Upcoming Investor Conferences in September
GL
08/23Truist Securities Lowers HOOKIPA Pharma's Price Target to $11 From $16, Maintains Buy R..
MT
08/12SVB Securities Adjusts HOOKIPA Pharma's Price Target to $3 From $4, Keeps Outperform Ra..
MT
08/11Hookipa Pharma : Reports Second Quarter 2022 Financial Results and Corporate Updates - For..
PU
08/11HOOKIPA PHARMA INC. Management's Discussion and Analysis of Financial Condition and Re..
AQ
08/11HOOKIPA Pharma Reports Second Quarter 2022 Financial Results and Corporate Updates
GL
08/11HOOKIPA Pharma Reports Second Quarter 2022 Financial Results and Corporate Updates
GL
08/11HOOKIPA Pharma Inc. Reports Earnings Results for the Second Quarter and Six Months Ende..
CI
08/04HOOKIPA Pharma to Report Second Quarter 2022 Financial Results on August 11, 2022
GL
07/25Hookipa Pharma Says FDA Accepts Investigational New Drug Application for Potential Pros..
MT
07/25FDA accepts HOOKIPA's Investigational New Drug Application for HB-300 for the treatment..
AQ
07/25Food and Drug Administration Accepts Hookipa’s Investigational New Drug Applicatio..
CI
07/13HOOKIPA Pharma Files $200 Million Mixed Shelf, Files Shelf on Behalf of Gilead Sciences
MT
07/01Hookipa Pharma : Amendments to Articles of Incorporation/Bylaws/Change in Fiscal Year - Fo..
PU
More news
News in other languages on HOOKIPA PHARMA INC.
08/11HOOKIPA Pharma Inc. annonce ses résultats pour le deuxième trimestre et le semestre clo..
07/25Hookipa Pharma déclare que la FDA accepte la demande de nouveau médicament de recherche..
07/25La Food and Drug Administration accepte la demande de nouveau médicament expérimental d..
07/13HOOKIPA Pharma dépose un panorama mixte de 200 millions de dollars et dépose un panoram..
06/21HOOKIPA Pharma Inc. annonce des changements au niveau de la direction
More news
Analyst Recommendations on HOOKIPA PHARMA INC.
More recommendations
ETFs positioned on HOOKIPA PHARMA INC.ETFs and Trackers with Trackinsight
ETF WeightVar. 5daysRatingGeography
ETFMG Treatments Testing and Advancements E...0.1%-0.43%-NC
IShares Micro-Cap ETF - USD0.02%-2.06%United_States
More ETFs positioned on HOOKIPA PHARMA INC.
Chart HOOKIPA PHARMA INC.
Duration : Period :
HOOKIPA Pharma Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends HOOKIPA PHARMA INC.
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 7
Last Close Price 1,46 $
Average target price 6,29 $
Spread / Average Target 331%
EPS Revisions
Managers and Directors
Jörn Aldag Chief Executive Officer & Director
Reinhard Kandera Chief Financial Officer
Jan G. J. van de Winkel Chairman
Roman Necina Chief Technology & Development Officer
Christine D. Baker Chief Operating Officer
Sector and Competitors
1st jan.Capi. (M$)
HOOKIPA PHARMA INC.-37.34%80
JOHNSON & JOHNSON-3.82%432 579
ELI LILLY AND COMPANY21.06%313 567
ROCHE HOLDING AG-15.52%269 089
ABBVIE INC.5.41%252 343
PFIZER, INC.-25.22%247 841